Recurrent respiratory papillomatosis: comparing in-office and operating room treatments.

IF 2.1 4区医学 Q2 OTORHINOLARYNGOLOGY

Acta Otorhinolaryngologica Italica Pub Date : 2024-08-01 DOI:10.14639/0392-100X-N2951

Marta Filauro, Alberto Vallin, Claudio Sampieri, Pietro Benzi, Giulia Gabella, Marta De Vecchi, Alessandro Ioppi, Francesco Mora, Giorgio Peretti

{"title":"Recurrent respiratory papillomatosis: comparing in-office and operating room treatments.","authors":"Marta Filauro, Alberto Vallin, Claudio Sampieri, Pietro Benzi, Giulia Gabella, Marta De Vecchi, Alessandro Ioppi, Francesco Mora, Giorgio Peretti","doi":"10.14639/0392-100X-N2951","DOIUrl":null,"url":null,"abstract":"Objective: We report the management of recurrent respiratory papillomatosis (RRP) employing a protocol that includes both office-based (OB) and general anaesthesia (GA) procedures. Quality of life (QoL) outcomes in the OB cohort were compared to those obtained from an historical cohort treated only under GA.Methods: Patients affected by RRP from 2019 until 2023 (\"new protocol\") and from 2012 to 2019 (\"historical protocol\") were enrolled. In both groups the Derkay site score (DSS) was calculated. In patients adhering to the new protocol, questionnaires measuring QoL were prospectively administered (voice handicap hindex-10 [VHI-10] along with a specific questionnaire to measure the tolerance to the OB procedures). A cost analysis was also performed.Results: In all, 35 patients composed the new protocol cohort and 13 the historical. In the first group, patients underwent a median of 4 treatments. At 2 years, 68% of patients were treated exclusively in the office. Overall, for the new protocol, median DSS and VHI-10 after one year were both significantly lower than those at baseline [2 vs 4 and 3 vs 14, respectively; p < 0.001]. No differences were found between the new and the historical protocol cohorts considering DSS over time.Conclusions: Treatment of RRP may be conducted successfully in an office-based setting reducing healthcare costs.","PeriodicalId":6890,"journal":{"name":"Acta Otorhinolaryngologica Italica","volume":"44 4","pages":"233-241"},"PeriodicalIF":2.1000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11441516/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Otorhinolaryngologica Italica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14639/0392-100X-N2951","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We report the management of recurrent respiratory papillomatosis (RRP) employing a protocol that includes both office-based (OB) and general anaesthesia (GA) procedures. Quality of life (QoL) outcomes in the OB cohort were compared to those obtained from an historical cohort treated only under GA.

Methods: Patients affected by RRP from 2019 until 2023 ("new protocol") and from 2012 to 2019 ("historical protocol") were enrolled. In both groups the Derkay site score (DSS) was calculated. In patients adhering to the new protocol, questionnaires measuring QoL were prospectively administered (voice handicap hindex-10 [VHI-10] along with a specific questionnaire to measure the tolerance to the OB procedures). A cost analysis was also performed.

Results: In all, 35 patients composed the new protocol cohort and 13 the historical. In the first group, patients underwent a median of 4 treatments. At 2 years, 68% of patients were treated exclusively in the office. Overall, for the new protocol, median DSS and VHI-10 after one year were both significantly lower than those at baseline [2 vs 4 and 3 vs 14, respectively; p < 0.001]. No differences were found between the new and the historical protocol cohorts considering DSS over time.

Conclusions: Treatment of RRP may be conducted successfully in an office-based setting reducing healthcare costs.

查看原文本刊更多论文

复发性呼吸道乳头状瘤病：诊室治疗与手术室治疗的比较。

目的：我们报告了复发性呼吸道乳头状瘤病（RRP）的治疗方案，该方案包括诊室手术（OB）和全身麻醉（GA）。将办公室治疗队列的生活质量（QoL）结果与仅在全身麻醉下治疗的历史队列的结果进行比较：招募了 2019 年至 2023 年（"新方案"）和 2012 年至 2019 年（"历史方案"）受 RRP 影响的患者。两组患者都计算了Derkay部位评分（DSS）。在遵循新方案的患者中，前瞻性地进行了QoL测量问卷调查（嗓音障碍指数-10[VHI-10]以及测量对转播手术耐受性的特定问卷）。此外，还进行了成本分析：共有 35 名患者接受了新方案治疗，13 名患者接受了历史方案治疗。第一组患者接受的治疗次数中位数为 4 次。2年后，68%的患者完全在诊室接受治疗。总体而言，新方案一年后的中位 DSS 和 VHI-10 均显著低于基线时的水平 [分别为 2 vs 4 和 3 vs 14；P < 0.001]。考虑到DSS随时间的变化，新方案和历史方案组群之间没有发现差异：结论：在诊室环境中治疗 RRP 可以成功降低医疗成本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Otorhinolaryngologica Italica OTORHINOLARYNGOLOGY-

CiteScore

3.40

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Acta Otorhinolaryngologica Italica first appeared as “Annali di Laringologia Otologia e Faringologia” and was founded in 1901 by Giulio Masini. It is the official publication of the Italian Hospital Otology Association (A.O.O.I.) and, since 1976, also of the Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale (S.I.O.Ch.C.-F.). The journal publishes original articles (clinical trials, cohort studies, case-control studies, cross-sectional surveys, and diagnostic test assessments) of interest in the field of otorhinolaryngology as well as clinical techniques and technology (a short report of unique or original methods for surgical techniques, medical management or new devices or technology), editorials (including editorial guests – special contribution) and letters to the Editor-in-Chief. Articles concerning science investigations and well prepared systematic reviews (including meta-analyses) on themes related to basic science, clinical otorhinolaryngology and head and neck surgery have high priority.